Business context and reporting period
ClearPoint Neuro, Inc. is a commercial-stage medical-device company focused on minimally invasive brain procedures, with products and services spanning neurosurgical navigation, biologics and drug delivery, and capital equipment and software. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2022; financial amounts below are in U.S. dollars unless indicated.
In September 2022, the ClearPoint Prism Neuro Laser Therapy System received FDA 510(k) clearance through the company’s Swedish partner, CLS. ClearPoint has exclusive global commercialization rights.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $5.15 million | $4.57 million | $15.38 million | $12.02 million |
| Gross profit | $3.71 million | $3.04 million | $10.22 million | $7.94 million |
| Gross margin | 72% | 66% | 66% | 66% |
| Operating loss | $(3.80) million | $(3.80) million | $(11.86) million | $(9.39) million |
| Net loss | $(3.79) million | $(3.98) million | $(12.05) million | $(10.26) million |
| Net loss per share | $(0.15) | $(0.18) | $(0.50) | $(0.50) |
At September 30, 2022, cash and cash equivalents were $18.7 million and short-term U.S. Treasury investments were $21.7 million, totaling $40.5 million in cash and investments. Current assets were $53.8 million and current liabilities $6.1 million. The company reported $10.0 million principal outstanding on a senior secured convertible note, due in 2025; its carrying value net of financing costs was $9.9 million. The note bears a floating rate, reported at 5.6% at quarter-end.
For the first nine months, operating cash use was $13.1 million, investing cash use was $22.5 million (primarily $21.6 million for Treasury investments), and financing provided $0.2 million. Cash and cash equivalents fell by $35.4 million to $18.7 million; the decline partly reflects funds held as short-term investments. Inventory was $8.3 million, up from $4.9 million at year-end 2021. Accumulated deficit was $146.0 million.
Material changes versus comparable periods
- Q3 revenue increased 13%; product revenue declined 6%, while service and other revenue rose 63%. Nine-month revenue increased 28%, with service and other revenue up 78% and product revenue up 10%.
- Nine-month revenue growth came from biologics and drug delivery (up 33%), capital equipment and software (up 78%), and functional neurosurgery navigation and therapy (up 15%). Management attributed growth principally to increased services, partner activity, and equipment placements.
- Nine-month gross margin held at 66%. Q3 margin improved to 72%, which management attributed to a higher share of higher-margin services and lower overhead, partly offset by higher excess and obsolete inventory reserves.
- Nine-month operating expenses increased: R&D 17%, sales and marketing 22%, and general and administrative 42%. Management cited personnel and development costs, marketing and travel, and higher share-based compensation.
- Nine-month net loss increased 17%, despite lower net interest expense, primarily reflecting higher operating expenses. Q3 net loss narrowed 5% year over year.
- The company reported approximately 50 biologics and drug-delivery partners at quarter-end, compared with approximately 40 a year earlier.
Outlook, risks, and unusual items
Management stated that existing cash, cash equivalents, and short-term investments were expected to fund operations and obligations for at least the next 12 months, based on current forecasts. The filing provides no specific revenue, earnings, or profitability guidance. Management said losses may continue as the company expands commercialization and develops additional applications.
Risks highlighted include inflation, supply-chain disruption, labor shortages, geopolitical instability, continuing COVID-19 effects, uncertain customer spending and partner commercialization, regulatory and clinical-development uncertainty, dependence on key suppliers, and future access to capital. The inventory buildup was described as a response to supply-chain disruptions. A 1–2 percentage-point increase in LIBOR above the note’s floor would add an estimated $0.3–$0.4 million of annual interest expense.
A pharmaceutical customer that is also a stockholder and noteholder, and has a board representative, accounted for 14% of Q3 sales and 16% of nine-month sales. No legal proceedings were reported. As a subsequent event, on November 4, 2022, the company entered into a lease for a Carlsbad office and manufacturing facility, with a term from June 2023 through May 2033 and initial base rent of approximately $36,978 per month, subject to annual increases of 3.5% and additional costs.
Important facts for investors to verify
- Whether revenue growth, particularly services and biologics and drug-delivery activity, continues and converts into durable commercial demand.
- Whether operating cash burn and inventory investment moderate; management’s 12-month liquidity assessment depends on forecasts and business conditions.
- The impact of inflation, supply constraints, inventory reserves, and customer or partner funding on margins and revenue.
- The terms and interest-rate exposure of the $10.0 million secured convertible note, including its 2025 maturity and conversion provisions.
- The commercial implications of Prism’s clearance, the new long-term facility lease, and the concentration of sales with the related-party customer.